KalVista Pharmaceuticals (KALV) Stock Analysis

What KalVista Pharmaceuticals does

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

Key metrics

ETFs linked to KALV

Broad-market and Healthcare sector ETFs an investor holding KalVista Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how KALV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for KalVista Pharmaceuticals?

KalVista Pharmaceuticals trades under the ticker KALV on NASDAQ.

Which exchange is KALV listed on?

KALV is listed on NASDAQ.

What sector does KalVista Pharmaceuticals operate in?

KalVista Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze KALV in a portfolio?

PortView shows KALV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.